English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduNeuroblastoma is a rare and aggressive form of childhood cancer. Striking in infancy, it shatters what should be a family’s time of joy, shifting it to a fight for survival. While the search for a cure continues, researchers at the University of South Australia are striving to decode the causes of neuroblastoma to inform new, less toxic treatment strategies for young patients.
Tag: Neuroblastoma
Cedars-Sinai Guerin Children’s Selects New Surgeon-in-Chief
Leading pediatric surgical oncologist Eugene Kim, MD, has been named the new surgeon-in-chief and associate director of Surgery at Cedars-Sinai Guerin Children’s.
Biotechnology CEO and Inventor of SiriusXM Satellite Radio Martine Rothblatt to Deliver Graduation Address to the University of Maryland School of Medicine’s 215th Graduating Class
University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, announced today that Martine Rothblatt PhD, JD, MBA, Chairperson and CEO of United Therapeutics, and inventor of SiriusXM Satellite Radio, will deliver the keynote address for this year’s graduating medical student class. The UMSOM MD graduation ceremony will take place at the Hippodrome Theatre on Thursday, May 16, 2024.
Change in MYCN-driven cell state opens therapeutic window in high-risk neuroblastoma
Scientists at St. Jude Children’s Research Hospital showed that the MYCN protein promotes a switch in the cellular state within the tumor microenvironment, with slow-growing mesenchymal cells swapping to the more dangerous and faster-growing adrenergic state.
Sara Federico, MD, named director of the Solid Tumor Division at St. Jude Children’s Research Hospital
Established clinician researcher will focus on novel treatments and clinical trials for difficult-to-treat childhood cancers.
Researchers Show Lorlatinib is Safe and Effective for Patients with ALK-Driven Relapsed/Refractory High-Risk Neuroblastoma
In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children’s Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma.
Novel targeted therapy could be effective treatment option for deadly childhood cancer
New research from VCU Massey Cancer Center — published Thursday in Cell Reports — demonstrated that a novel targeted therapy could be an effective treatment option for a deadly pediatric cancer known as neuroblastoma.
Children’s Hospital Los Angeles Offers MIBG Therapy for Neuroblastoma
Children with high-risk neuroblastoma can now access a specialized, targeted radiation treatment called MIBG therapy at Children’s Hospital Los Angeles—one of the largest neuroblastoma programs in the country and the only pediatric facility in Southern California and the Southwestern United States to offer this treatment.
“Bridge therapy” may benefit some children with high-risk neuroblastoma
Additional therapy between two standard phases of treatment may be especially effective in patients with stable metastatic cancer.
Safety concerns raised for neuroblastoma candidate drug
St. Jude Children’s Research Hospital scientists have identified the primary target of the experimental cancer drug CX-5164, revealing a possible risk for late effects of treatment.
CHOP Researchers Develop a New Class of CAR-T Cells that Target Previously Untargetable Cancer Drivers
In a breakthrough for the treatment of aggressive solid cancers, researchers at Children’s Hospital of Philadelphia (CHOP) have developed a novel cancer therapy that targets proteins inside cancer cells that are essential for tumor growth and survival but have been historically impossible to reach. Using the power of large data sets and advanced computational approaches, the researchers were able to identify peptides that are presented on the surface of tumor cells and can be targeted with “peptide-centric” chimeric antigen receptors (PC-CARs), a new class of engineered T cells, stimulating an immune response that eradicates tumors.
Are childhood cancers different? Understanding the immune response to tumors in pediatric neuroblastoma
UChicago Medicine physician-scientists aimed to find out how the immune systems of children with a type of cancer called neuroblastoma respond to tumors. The answer to this question could help guide the treatment of pediatric patients.
Therapy Using Dual Immune System Cells Effectively Controls Neuroblastoma
A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was highly effective in mice implanted with human neuroblastoma tissue.
The hunt to find causes and treatments for deadly childhood cancer
Neuroblastoma is the deadliest and most common solid cancer in young children the world over, accounting for 15 per cent of all childhood cancer deaths. But Australian researchers are taking the first steps to find the cause and better treatments for this devastating disease which affects children under the age of five.
Investigadores de Mayo Clinic identifican gen implicado en el neuroblastoma
Un nuevo estudio de los investigadores de Mayo Clinic identificó que un gen de inestabilidad cromosómica, el USP24, está a menudo ausente en los pacientes pediátricos con neuroblastoma (tipo agresivo de cáncer cerebral en niños). El resultado ofrece una perspectiva importante sobre el desarrollo de esta enfermedad.
Researchers identify gene implicated in neuroblastoma, a childhood cancer
A new study by Mayo Clinic researchers has identified that a chromosome instability gene, USP24, is frequently missing in pediatric patients with neuroblastoma, an aggressive form of childhood cancer. The finding provides important insight into the development of this disease. The study is published in Cancer Research, the journal of the American Association for Cancer Research.
Researchers mine data and connect the dots about processes driving neuroblastoma
Researchers have used insight from a comprehensive genomic analysis of neuroblastoma to learn about the process driving one of the most common childhood solid tumors.
Researchers Identify Targeted Therapy That Can Help Children With Deadly Nerve Cancer
Mount Sinai researchers have identified a targeted therapy for adolescent patients with neuroblastoma, a deadly pediatric nerve cancer, who would otherwise have no treatment options, according to a study published in October in Cancer Cell.
Algorithm Reduces Need for Therapy in Children With Intermediate-Risk Neuroblastoma
Roswell Park’s Dr. Clare Twist led an effort to develop and validate a new treatment algorithm for infants and children with neuroblastoma. In a new study in the Journal of Clinical Oncology, the team reports that many patients can safely receive less extensive therapy.